Skip to content

Current ratio at other companies

Eli Lilly logo
Eli LillyLLY
1.5×+0.1×
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
4.6×+0.6×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
4.1×-5.6×
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
3.5×-2.4×
ALN
Alnylam PharmaceuticalsALNY
3.1×+0.1×
Beam Therapeutics logo
Beam TherapeuticsBEAM
17×+8.2×

Other financials

Income statement

See full
Revenue$38.2M+317%
Operating income-$31.3M+37.2%
Net income-$26.1M+44.4%
EPS (diluted)-$0.13+55.2%

Balance sheet

See full
Cash & equivalents$544.6M+124%
Total debt$15.7M-33.4%
Total equity$511.7M+198%
Total assets$583.5M+102%

Cash flow

See full
Operating cash flow-$59.6M+5.5%
CapEx$438.0K+165%
Free cash flow-$60.0M+5.1%

Valuation

See full
Market cap$1.14B+13.0%
Enterprise value$615.92M-22.3%
P/S15.1×-12.2×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-53.7%
Debt / equity-0.1×

Where this comes from

Calculated from Wave Life Sciences’s reported figures.

Based on the most recent quarter.

The official record: Wave Life Sciences’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Wave Life Sciences's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Wave Life Sciences's current ratio?
Wave Life Sciences (WVE) reported current ratio of 11.3× in Q1 2026.
How has Wave Life Sciences's current ratio changed year-over-year?
Wave Life Sciences's current ratio increased by 281.5% year-over-year, from 3× to 11.3×.
What is the long-term trend for Wave Life Sciences's current ratio?
Over 5 years (2020 to 2025), Wave Life Sciences's current ratio has grown at a 27.8% compound annual growth rate (CAGR), from 1.9× to 6.5×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.